Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-12-21Clinical Trial Update: A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea
A completed non-interventional study in Korea monitored safety and effectiveness of Trajenta Duo for type 2 diabetes; results posted in 2018…
-
FDA approval · 2018-12-20FDA Approved: BYETTA — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for BYETTA (exenatide) submitted by AstraZeneca Pharmaceuticals LP. The action updates the labeling …
-
FDA approval · 2018-12-20FDA Approved: APIDRA — Supplemental Application (sanofi-aventis U.S. LLC)
The FDA approved a supplemental application for APIDRA (insulin glulisine) submitted by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2018-12-17FDA Approved: PIOGLITAZONE — Supplemental Application (NorthStar RxLLC)
The FDA approved a supplemental application for pioglitazone submitted by NorthStar RxLLC. This action adds to the existing approval of the …
-
CLINICAL_TRIALS trial_result · 2018-12-14Clinical Trial Update: Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes [Phase 4]
A Phase 4 trial evaluating anakinra for efficacy in patients with rheumatoid arthritis and type 2 diabetes has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-12-11FDA Approved: INSULIN LISPRO — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental Biologics License Application for insulin lispro from Eli Lilly, authorizing changes to the product's labeli…
-
CLINICAL_TRIALS trial_result · 2018-12-11Clinical Trial Update: A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus [Phase 4]
Phase 4 trial evaluating the effects of canagliflozin on renal endpoints in adults with type 2 diabetes and albuminuria; completed with resu…
-
CLINICAL_TRIALS trial_result · 2018-12-10Clinical Trial Update: An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus [Phase 4]
Exploratory Phase 4 trial evaluating the effects of trelagliptin and alogliptin on glucose variability in adults with type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2018-12-07Clinical Trial Update: CANVAS - CANagliflozin cardioVascular Assessment Study [Phase 3]
Phase 3 CANVAS trial assessing canagliflozin for cardiovascular outcomes in type 2 diabetes; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-12-07Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012) [Phase 3]
Phase 3 study evaluating ertugliflozin in Asian participants with Type 2 diabetes inadequately controlled on metformin; study completed with…
-
CLINICAL_TRIALS trial_result · 2018-12-07Clinical Trial Update: Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes [Phase 3]
Phase 3 trial comparing efficacy and safety of insulin degludec/insulin aspart combination versus BIAsp 30 in adults with type 2 diabetes.
-
FDA approval · 2018-11-30FDA Approved: NATEGLINIDE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for nateglinide by Dr. Reddy's Laboratories Limited.
-
FDA approval · 2018-11-30FDA Approved: PIOGLITAZONE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Pioglitazone hydrochloride from Aurobindo Pharma Limited, updating an already approved product.
-
FDA approval · 2018-11-29FDA Approved: LANTUS SOLOSTAR — Supplemental Application (sanofi-aventis U.S. LLC)
The FDA approved a supplemental application for LANTUS SOLOSTAR (insulin glargine) submitted by sanofi-aventis U.S. LLC.
-
FDA approval · 2018-11-26FDA Approved: PIOGLITAZONE HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for pioglitazone hydrochloride (generic), with Chartwell RX, LLC listed as the sponsor/manufacturer.
-
FDA approval · 2018-11-26FDA Approved: PIOGLITAZONE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for Pioglitazone (generic) under ANDA. Pioglitazone is used to treat type 2 diabetes mellitus.
-
FDA approval · 2018-11-26FDA Approved: GLIMEPIRIDE — Supplemental Application (Florida Pharmaceutical Products, LLC)
FDA approved a supplemental application for glimepiride from Florida Pharmaceutical Products, LLC.
-
CLINICAL_TRIALS trial_result · 2018-11-21Clinical Trial Update: Combined Rg3-enriched Korean Red Ginseng and American Ginseng in the Management of Hypertension in Type 2 Diabetes [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating combined Rg3-enriched Korean Red Ginseng and American Ginseng for managing hypertension in individuals w…
-
CLINICAL_TRIALS trial_result · 2018-11-20Clinical Trial Update: Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide in Type 2 Diabetes [Phase 4]
A Phase 4 clinical trial comparing short-term effects of perindopril-amlodipine versus perindopril-indapamide in patients with type 2 diabet…
-
FDA approval · 2018-11-19FDA Approved: NATEGLINIDE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Nateglinide from Zydus Lifesciences Limited.
-
CLINICAL_TRIALS trial_result · 2018-11-19Clinical Trial Update: Telemedicine Strategy With Home Treatment Save Resources [NA]
Completed clinical trial evaluating a telemedicine strategy with home treatment for type 2 diabetes mellitus; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-11-15Clinical Trial Update: Konjac-Mannan Improves Glycemia and Other Risk Factors for CHD in T2DM [Phase 2]
A Phase 2 trial evaluating konjac-mannan shows improvements in glycemia and other cardiovascular risk factors in individuals with type 2 dia…
-
CLINICAL_TRIALS trial_result · 2018-11-14Clinical Trial Update: Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM [Phase 4]
Phase 4 trial comparing basal insulin glargine in combination with exenatide twice daily versus insulin aspart in type 2 diabetes mellitus; …
-
CLINICAL_TRIALS withdrawal · 2018-11-14Clinical Trial Update: Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment [Phase 2, Phase 3]
A Phase 2/Phase 3 study evaluating berberine hydrochloride and bifidobacterium for Type 2 diabetes mellitus was withdrawn.
-
CLINICAL_TRIALS trial_result · 2018-11-14Clinical Trial Update: Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes [Phase 4]
Phase 4 trial comparing exenatide with biphasic insulin aspart 30 for glucose variability in adults with type 2 diabetes has been completed.